The Value of Botox-A in Acute Radiation Proctitis: Results From a Phase I/II Study Using a Three-Dimensional Scoring System
- Department of Radiation Oncology, McGill University, Montreal (Canada)
- Department of Gastroenterology, McGill University, Montreal (Canada)
- Department of Colorectal Surgery, Universite de Montreal, Montreal (Canada)
- Department of Colorectal Surgery, McGill University, Montreal (Canada)
- Department of Medical Physics, McGill University, Montreal (Canada)
Purpose: Acute radiation proctitis (ARP) is a common side effect of pelvic radiotherapy, and its management is challenging in daily practice. The present phase I/II study evaluates the safety and efficacy of the botulinum toxin A (BTX-A) in ARP treatment for rectal cancer patients undergoing neoadjuvant high-dose-rate endorectal brachytherapy (HDREBT). Methods and Materials: Fifteen patients, treated with neoadjuvant HDREBT, 26-Gy in 4 fractions, received the study treatment that consisted of a single injection of BTX-A into the rectal wall. The injection was performed post-HDREBT and prior to the development of ARP. The control group, 20 such patients, did not receive the BTX-A injection. Both groups had access to standard treatment with hydrocortisone rectal aerosol foam (Cortifoam) and anti-inflammatory and narcotic medication. The ARP was clinically evaluated by self-administered daily questionnaires using visual analog scores to document frequency and urgency of bowel movements, rectal burning/tenesmus, and pain symptoms before and after HDREBT. Results: At the time of this analysis, there was no observed systemic toxicity. Patient compliance with the self-administered questionnaire was 100% from week 1 to 4, 70% during week 5, and 40% during week 6. The maximum tolerated dose was established at the 100-U dose level, and noticeable mean differences were observed in bowel frequency (p = 0.016), urgency (p = 0.007), and pain (p = 0.078). Conclusions: This study confirms the feasibility and efficacy of BTX-A intervention at 100-U dose level for study patients compared to control patients. A phase III study with this dose level is planned to validate these results.
- OSTI ID:
- 21587671
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 80, Issue 5; Other Information: DOI: 10.1016/j.ijrobp.2010.04.017; PII: S0360-3016(10)00590-0; Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Dose-Volume Effects on Patient-Reported Acute Gastrointestinal Symptoms During Chemoradiation Therapy for Rectal Cancer
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading
Related Subjects
BRACHYTHERAPY
DOSE RATES
HYDROCORTISONE
INFLAMMATION
NARCOTICS
NEOPLASMS
PROCTITIS
RADIATION DOSES
RADIATION INJURIES
RECTUM
SIDE EFFECTS
TOXINS
ADRENAL HORMONES
ANTIGENS
BIOLOGICAL EFFECTS
BIOLOGICAL RADIATION EFFECTS
BODY
CENTRAL NERVOUS SYSTEM AGENTS
CENTRAL NERVOUS SYSTEM DEPRESSANTS
CORTICOSTEROIDS
DIGESTIVE SYSTEM
DIGESTIVE SYSTEM DISEASES
DISEASES
DOSES
DRUGS
GASTROINTESTINAL TRACT
GLUCOCORTICOIDS
HAZARDOUS MATERIALS
HORMONES
HYDROXY COMPOUNDS
INJURIES
INTESTINES
KETONES
LARGE INTESTINE
MATERIALS
MEDICINE
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANS
PATHOLOGICAL CHANGES
PREGNANES
RADIATION EFFECTS
RADIOLOGY
RADIOTHERAPY
STEROID HORMONES
STEROIDS
SYMPTOMS
THERAPY
TOXIC MATERIALS